No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
zanubrutinib
BeiGene Press Release - 4 days
|
No biomarker
No biomarker
|
Acute Lymphocytic Leukemia
ALL
|
eryaspase
Sensitive: B - Late Trials
- 4 days
|
No biomarker
No biomarker
|
Acute Lymphocytic Leukemia
ALL
|
recombinant Erwinia asparaginase
Jazz Pharma Press Release - 1 week
|
TP53 mutation
TP53 mutation
|
Acute Myelogenous Leukemia
AML
|
APR-246
Sensitive: B - Late Trials
Aprea Press Release - 1 week
|
NRAS mutation
NRAS mutation
|
Acute Myelogenous Leukemia
AML
|
azacitidine
Resistant: B - Late Trials
Acta Haematol - 3 weeks
|
NRAS mutation
NRAS mutation
|
Acute Myelogenous Leukemia
AML
|
decitabine
Resistant: C3 – Early Trials
Acta Haematol - 3 weeks
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
Truxima (rituximab biosimilar)
|
FLT3 mutation
FLT3 mutation
|
Acute Myelogenous Leukemia
AML
|
|
IDH2 mutation
IDH2 mutation
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
No biomarker
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
cytarabine/daunorubicin liposomal formulation
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Chronic Myeloid Leukemia
CML
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
FLT3 mutation
FLT3 mutation
|
Acute Myelogenous Leukemia
AML
|
|
CD33 positive
CD33 positive
|
Acute Myelogenous Leukemia
AML
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Chronic Myeloid Leukemia
CML
|
omacetaxine mepesuccinate
|
CD22 positive
CD22 positive
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
CD20 expression
CD20 expression
|
Chronic Lymphocytic Leukemia
CLL
|
|
BCR-ABL1 T315I
BCR-ABL1 T315I
|
Chronic Myeloid Leukemia
CML
|
|
BCR-ABL1 T315I
BCR-ABL1 T315I
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
Chronic Myeloid Leukemia
CML
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Truxima (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Rixathon (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Acute Lymphocytic Leukemia
ALL
|
|
|
Chronic Myeloid Leukemia
CML
|
|
Chr t(1;16)(q12;q11.2)
Chr t(1;16)(q12;q11.2)
|
Chronic Myeloid Leukemia
CML
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
T Acute Lymphoblastic Leukemia
T Acute Lymphoblastic Leukemia
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
CD19 positive
CD19 positive
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
Hairy Cell Leukemia
Hairy Cell Leukemia
|
|
Chr t(15;17)
Chr t(15;17)
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
|
PML-RARA fusion
PML-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Myeloid Leukemia
CML
|
|
No biomarker
No biomarker
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
No biomarker
No biomarker
|
Chronic Myelomonocytic Leukemia
CMML
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Chronic Myeloid Leukemia
CML
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
IDH1 mutation
IDH1 mutation
|
Acute Myelogenous Leukemia
AML
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Chronic Myeloid Leukemia
CML
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
BCR-ABL1 fusion
BCR-ABL1 fusion
|
Chronic Myeloid Leukemia
CML
|
|
No biomarker
No biomarker
|
Acute Lymphocytic Leukemia
ALL
|
|
No biomarker
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia
|
|
No biomarker
No biomarker
|
Hairy Cell Leukemia
Hairy Cell Leukemia
|
|
CD19 positive
CD19 positive
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Myelomonocytic Leukemia
CMML
|
|
No biomarker
No biomarker
|
Acute Myelogenous Leukemia
AML
|
|
CD20 positive
CD20 positive
|
Chronic Lymphocytic Leukemia
CLL
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
PCR
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ofatumumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Chronic Lymphocytic Leukemia
CLL
|
FCR
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Sensitive: A2 - Guideline
|
BCR-ABL1 V299L
BCR-ABL1 V299L
|
Acute Lymphocytic Leukemia
ALL
|
dasatinib
Resistant: A2 - Guideline
|
IDH2 mutation
IDH2 mutation
|
Acute Myelogenous Leukemia
AML
|
venetoclax
Sensitive: A2 - Guideline
|
IDH1 mutation
IDH1 mutation
|
Acute Myelogenous Leukemia
AML
|
venetoclax
Sensitive: A2 - Guideline
|
BCR-ABL1 F317I
BCR-ABL1 F317I
|
Acute Lymphocytic Leukemia
ALL
|
dasatinib
Resistant: A2 - Guideline
|
BCR-ABL1 T315I
BCR-ABL1 T315I
|
Acute Lymphocytic Leukemia
ALL
|
dasatinib
Resistant: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
